DUCHESS: an evaluation of the ductal carcinoma in situ score for decisions on radiotherapy in patients with low/intermediate-risk DCIS.
Assay
DCIS
De-escalation
Ductal carcinoma in situ
Genomic
Radiotherapy
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
05
12
2020
accepted:
10
03
2021
pubmed:
9
4
2021
medline:
30
6
2021
entrez:
8
4
2021
Statut:
ppublish
Résumé
Identification of women with DCIS who have a very low risk of local recurrence risk (LRR) after breast-conserving surgery (BCS) is needed to de-escalate therapy. We evaluated the impact of 10-year LRR estimates after BCS, calculated by the integration of a 12-gene molecular expression assay (Oncotype Breast DCIS Score Prospective cohort study of women with DCIS treated with BCS. Eligibility criteria were as follows: age > 45 years, tumor ≤ 2.5 cm, and margins ≥ 1 mm. Radiation oncologists provided 10-year LRR estimates without RT and recommendation for RT pre- and post-assay. Primary outcome was change in RT recommendation. 217 patients were evaluable, with mean age = 63 years, mean tumor size = 1.1 cm, and mean DCIS Score = 32; 140 (64%) were in the low-risk (<39), 32 (15%) were in the intermediate-risk (39-54), and 45 (21%) were in the high-risk groups (≥55). The assay led to a change in treatment recommendation in 76 (35.2%) (95%CI 29.1-41.8%) patients. RT recommendations decreased from 79% pre-assay to 50% post-assay (difference = 29%; 95%CI 22-35%) due to a significant increase in the proportion of patients with a predicted low LRR (< 10%) post-assay and recommendations to omit RT for those with a low predicted risk. The assay was associated with improved patient satisfaction and reduced decisional conflict. The DCIS Score assay combined with CPFs identified more women with an estimated low (<10%) 10-yr LR risk after BCS, leading to a significant decrease in recommendations for RT compared to estimates based on CPFs alone.
Sections du résumé
BACKGROUND
BACKGROUND
Identification of women with DCIS who have a very low risk of local recurrence risk (LRR) after breast-conserving surgery (BCS) is needed to de-escalate therapy. We evaluated the impact of 10-year LRR estimates after BCS, calculated by the integration of a 12-gene molecular expression assay (Oncotype Breast DCIS Score
METHODS
METHODS
Prospective cohort study of women with DCIS treated with BCS. Eligibility criteria were as follows: age > 45 years, tumor ≤ 2.5 cm, and margins ≥ 1 mm. Radiation oncologists provided 10-year LRR estimates without RT and recommendation for RT pre- and post-assay. Primary outcome was change in RT recommendation.
RESULTS
RESULTS
217 patients were evaluable, with mean age = 63 years, mean tumor size = 1.1 cm, and mean DCIS Score = 32; 140 (64%) were in the low-risk (<39), 32 (15%) were in the intermediate-risk (39-54), and 45 (21%) were in the high-risk groups (≥55). The assay led to a change in treatment recommendation in 76 (35.2%) (95%CI 29.1-41.8%) patients. RT recommendations decreased from 79% pre-assay to 50% post-assay (difference = 29%; 95%CI 22-35%) due to a significant increase in the proportion of patients with a predicted low LRR (< 10%) post-assay and recommendations to omit RT for those with a low predicted risk. The assay was associated with improved patient satisfaction and reduced decisional conflict.
CONCLUSION
CONCLUSIONS
The DCIS Score assay combined with CPFs identified more women with an estimated low (<10%) 10-yr LR risk after BCS, leading to a significant decrease in recommendations for RT compared to estimates based on CPFs alone.
Identifiants
pubmed: 33830392
doi: 10.1007/s10549-021-06187-7
pii: 10.1007/s10549-021-06187-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
133-139Références
Cancer NCPGB (2020).
Worni M, Akushevich I, Greenup R, Sarma D, Ryser MD, Myers ER, Hwang ES (2015) Trends in treatment patterns and outcomes for ductal carcinoma in situ. JNCI. https://doi.org/10.1093/jnci/djv263
doi: 10.1093/jnci/djv263
pubmed: 26683405
pmcid: 4849804
Hwang ES, Hyslop T, Lynch T, Frank E, Pinto D, Basila D, Collyar D, Bennett A, Kaplan C, Rosenberg S, Thompson A, Weiss A, Partridge A (2019) The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS). BMJ Open 9(3):e026797. https://doi.org/10.1136/bmjopen-2018-026797
doi: 10.1136/bmjopen-2018-026797
pubmed: 6429899
pmcid: 6429899
Francis A, Fallowfield L, Rea D (2015) The LORIS trial: addressing overtreatment of ductal carcinoma in situ. Clin Oncol (R Coll Radiol) 27(1):6–8. https://doi.org/10.1016/j.clon.2014.09.015
doi: 10.1016/j.clon.2014.09.015
Elshof LE, Tryfonidis K, Slaets L, van Leeuwen-Stok AE, Skinner VP, Dif N, Pijnappel RM, Bijker N, Rutgers EJ, Wesseling J (2015) Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study. Eur J Cancer (Oxford, England) 51(12):1497–1510. https://doi.org/10.1016/j.ejca.2015.05.008
doi: 10.1016/j.ejca.2015.05.008
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817–2826. https://doi.org/10.1056/NEJMoa041588
doi: 10.1056/NEJMoa041588
Solin LJ, Gray R, Baehner FL, Butler SM, Hughes LL, Yoshizawa C, Cherbavaz DB, Shak S, Page DL, Sledge GW Jr, Davidson NE, Ingle JN, Perez EA, Wood WC, Sparano JA, Badve S (2013) A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst 105(10):701–710. https://doi.org/10.1093/jnci/djt067
doi: 10.1093/jnci/djt067
pubmed: 23641039
pmcid: 3653823
Rakovitch E, Nofech-Mozes S, Hanna W, Baehner FL, Saskin R, Butler SM, Tuck A, Sengupta S, Elavathil L, Jani PA, Bonin M, Chang MC, Robertson SJ, Slodkowska E, Fong C, Anderson JM, Jamshidian F, Miller DP, Cherbavaz DB, Shak S, Paszat L (2015) A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone. Breast Cancer Res Treat 152(2):389–398. https://doi.org/10.1007/s10549-015-3464-6
doi: 10.1007/s10549-015-3464-6
pubmed: 26119102
pmcid: 4491104
Rakovitch E, Gray R, Baehner FL, Sutradhar R, Crager M, Gu S, Nofech-Mozes S, Badve SS, Hanna W, Hughes LL, Wood WC, Davidson NE, Paszat L, Shak S, Sparano JA, Solin LJ (2018) Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies. Breast Cancer Res Treat 169(2):359–369. https://doi.org/10.1007/s10549-018-4693-2
doi: 10.1007/s10549-018-4693-2
pubmed: 29388015
pmcid: 5945747
Paszat L, Sutradhar R, Zhou L, Nofech-Mozes S, Rakovitch E (2019) Including the Ductal Carcinoma-In-Situ (DCIS) score in the development of a multivariable prediction model for recurrence after excision of DCIS. Clin Breast Cancer 19(1):35–46. https://doi.org/10.1016/j.clbc.2018.07.018
doi: 10.1016/j.clbc.2018.07.018
pubmed: 30190195
O’Connor AM (1995) Validation of a decisional conflict scale. Med Decis Making 15(1):25–30. https://doi.org/10.1177/0272989x9501500105
doi: 10.1177/0272989x9501500105
pubmed: 7898294
Rudloff U, Jacks LM, Goldberg JI, Wynveen CA, Brogi E, Patil S, Van Zee KJ (2010) Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ. J Clin Oncol 28(23):3762–3769
doi: 10.1200/JCO.2009.26.8847
Silverstein MJ, Lagios MD (2015) Treatment selection for patients with ductal carcinoma in situ (DCIS) of the breast using the University of Southern California/Van Nuys (USC/VNPI) prognostic index. Breast J 21(2):127–132. https://doi.org/10.1111/tbj.12368
doi: 10.1111/tbj.12368
pubmed: 25600630
McCormick B, Winter K, Hudis C, Kuerer HM, Rakovitch E, Smith BL, Sneige N, Moughan J, Shah A, Germain I, Hartford AC, Rashtian A, Walker EM, Yuen A, Strom EA, Wilcox JL, Vallow LA, Small W Jr, Pu AT, Kerlin K, White J (2015) RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol 33(7):709–715. https://doi.org/10.1200/JCO.2014.57.9029
doi: 10.1200/JCO.2014.57.9029
pubmed: 25605856
pmcid: 4334775
Solin LJ, Gray R, Hughes LL, Wood WC, Lowen MA, Badve SS, Baehner FL, Ingle JN, Perez EA, Recht A, Sparano JA, Davidson NE (2015) Surgical excision without radiation for ductal carcinoma in situ of the breast: 12-year results from the ECOG-ACRIN E5194 study. J Clin Oncol 33(33):3938–3944. https://doi.org/10.1200/JCO.2015.60.8588
doi: 10.1200/JCO.2015.60.8588
pubmed: 26371148
pmcid: 4652014
Wong JS, Kaelin CM, Troyan SL, Gadd MA, Gelman R, Lester SC, Schnitt SJ, Sgroi DC, Silver BJ, Harris JR, Smith BL (2006) Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol 24(7):1031–1036. https://doi.org/10.1200/jco.2005.02.9975
doi: 10.1200/jco.2005.02.9975
pubmed: 16461781
Rakovitch E, Nofech-Mozes S, Narod S, Hanna W, Thiruchelvam D, Saskin R, Taylor C, Tuck A, Sengupta S, Elavathil L, Jani P, Done S, Miller N, Youngson B, Kong I, Paszat L (2013) Can we select individuals with low risk ductal carcinoma in situ (DCIS)? a population-based outcomes analysis. Breast Cancer Res Treat 138(2):581–590
doi: 10.1007/s10549-013-2455-8
Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA Jr, Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW (2015) Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 373(21):2005–2014. https://doi.org/10.1056/NEJMoa1510764
doi: 10.1056/NEJMoa1510764
pubmed: 26412349
pmcid: 26412349
Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr (2019) Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med 380(25):2395–2405. https://doi.org/10.1056/NEJMoa1904819
doi: 10.1056/NEJMoa1904819
pubmed: 6709671
pmcid: 6709671
Alvarado M, Carter DL, Guenther JM, Hagans J, Lei RY, Leonard CE, Manders J, Sing AP, Broder MS, Cherepanov D, Chang E, Eagan M, Hsiao W, Schultz MJ (2015) The impact of genomic testing on the recommendation for radiation therapy in patients with ductal carcinoma in situ: a prospective clinical utility assessment of the 12-gene DCIS score result. J Surg Oncol 111(8):935–940. https://doi.org/10.1002/jso.23933
doi: 10.1002/jso.23933
pubmed: 26031501
Manders JB, Kuerer HM, Smith BD, McCluskey C, Farrar WB, Frazier TG, Li L, Leonard CE, Carter DL, Chawla S, Medeiros LE, Guenther JM, Castellini LE, Buchholz DJ, Mamounas EP, Wapnir IL, Horst KC, Chagpar A, Evans SB, Riker AI, Vali FS, Solin LJ, Jablon L, Recht A, Sharma R, Lu R, Sing AP, Hwang ES, White J (2017) Clinical utility of the 12-gene DCIS score assay: impact on radiotherapy recommendations for patients with ductal carcinoma in situ. Ann Surg Oncol 24(3):660–668. https://doi.org/10.1245/s10434-016-5583-7
doi: 10.1245/s10434-016-5583-7
pubmed: 27704370